Source: ERJ Open Res 2015
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D'Ambrosio Lia, Centis Rosella, Sotgiu Giovanni, Pontali Emanuele, Spanevello Antonio, Migliori Giovanni Battista. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res 2015; 1: 00010-2015

Member's Comments

No comment yet.

Related content which might interest you: New anti-tuberculosis drugs for special populations: a difficult-to-address issue Source: Eur Respir J 2016; 48: 957-958 Year: 2016 Availability of anti-tuberculosis drugs in Europe Source: Eur Respir J 2012; 40: 500-503 Year: 2012 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016 New and repurposed drugs for MDR-TB patients Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence  Year: 2017 Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy Source: Eur Respir J 2012; 39: 1263-1266 Year: 2012 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe Source: Eur Respir J, 58 (3) 2101196; 10.1183/13993003.01196-2021 Year: 2021 Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021 New methodologogic approaches to the management of antituberculous service Source: Eur Respir J 2003; 22: Suppl. 45, 381s Year: 2003 Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey Source: Eur Respir J 2015; 45: 1081-1088 Year: 2015 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 New and repurposed TB drugs use in children and adolescents with M/XDR-TB Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008